The SITC Sparkathon – Emerging Leaders, Igniting Innovation is an exciting opportunity for early career professionals seeking to participate in new research that contributes to the cancer immunotherapy field and the society as a whole.
Following an application process, a group of 30 emerging leaders will explore the critical hurdles that have challenged this field for years. Once projects have been determined, teams will formulate plans to solve the major issues. Participants will have access to leadership experts who will assist teams in developing their proposals for successful implementation.
Projects will be presented to a panel of SITC leaders who will select the top proposals for implementation.
But first ...
Before SITC can open the Sparkathon application process and attempt to make a large leap forward in research, the society must meet its goal to raise $600,000. An anonymous donor has pledged to DOUBLE all donations made to the Forward Fund, meaning the society has been challenged to raise $300,000 over the next two years ($150,000 per year) for this special initiative.
Now is the time to ignite the Sparkathon!
If SITC reaches its goal, $600,000 will help create a unique opportunity for the society’s early career professionals to tackle the biggest hurdles facing the future of the research. Consider making a pledge or contribution to the Forward Fund now and make twice the impact on the society and a lasting difference for the future of cancer immunotherapy.
To have your SITC Sparkathon donation doubled, text SPARK to 50555 to donate $25 or click the button below to contribute online.
As a 501(c)(3) organization, donations made to SITC are tax deductible as a charitable contribution to the extent allowed by law.
Immunotherapy@Brisbane 2017 Register online before Friday April 21! Final Program Released
EMBO KEYNOTE LECTURE Professor Sir Marc Feldmann Kennedy Institute of Rheumatology, University of Oxford, UK KEY SPEAKER Professor Shimon ...
This message was posted by a user wishing to remain anonymous Another Great Pittsburgher Dies - Philanthropist Henry Hillman led the renaissance of Pittsburgh's rebirth, a benefactor of the Hillman Cancer Center, an NCI Designated Cancer Center. http://www.post-gazette.com/local/city/2017/04/14/Philanthropist-Henry-Hillman-dies/stories/201704140181
Published April 11, 2017, in JAMA are the United States Preventative Services Task Force new recommendations for the surveillance of Prostate Cancer. The USPSTF recommends that the decision to have a DRE and prostate screening with PSA should be up ...
Immunotherapy@Brisbane 2017 Register online before Friday April 21! Leading International Speakers
EMBO KEYNOTE LECTURE Professor Sir Marc Feldmann Kennedy Institute of Rheumatology, University of Oxford, UK KEY SPEAKER ...
Greetings SITC researchers: Prostate cancer is not very responsive to immune checkpoint blockade (ICB). Why is that? A "Nature" journal paper just out (3/29/17 currently online only) appears to add a "secret sauce" that combines Immune checkpoint blockade ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com